Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

FHS
June 12, 2024
10:52 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

Australian researchers discover how COVID-19 can infect the human placenta

In a landmark study published in Nature Cell Biology, Australian researchers, led by Professor Jose Polo from Monash University and the University of Adelaide and

July 14, 2023

FDA withdraws from Global Harmonization Working Party

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The U.S. Food and Drug

November 27, 2023

Modified darobactin offers hope for combatting antibiotic-resistant bacteria

Antibacterial drugs are important for treating infections. But increasingly, bacterial resistance to current drugs -; so they don’t work well, or even at all -;

November 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.